Core Insights - Foghorn Therapeutics is advancing its pipeline, particularly focusing on FHD-909, a first-in-class oral SMARCA2 selective inhibitor, which is currently in a Phase 1 dose escalation trial targeting non-small cell lung cancer (NSCLC) [1][3][4] - The company has shown promising preclinical data indicating synergistic effects of FHD-909 when combined with pembrolizumab and KRAS inhibitors, suggesting significant potential in treating difficult-to-treat NSCLC [2][4] - Foghorn's selective degrader programs targeting CBP, EP300, and ARID1B are progressing well, with updates expected in Q4 2025 and an IND application for the Selective CBP degrader anticipated in 2026 [2][6][12] Financial Overview - As of June 30, 2025, Foghorn reported cash, cash equivalents, and marketable securities totaling $198.7 million, providing a cash runway into 2028 [1][18] - Collaboration revenue for the three months ended June 30, 2025, was $7.6 million, an increase from $6.9 million in the same period in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [10][21] - The net loss for the three months ended June 30, 2025, was $17.9 million, compared to a net loss of $23.0 million for the same period in 2024, indicating improved financial performance [18][21] Pipeline and Development Programs - FHD-909 is designed to selectively inhibit SMARCA2, which is crucial for the survival of tumors with SMARCA4 mutations, and has shown significant anti-tumor activity in preclinical models [3][13] - The Selective CBP degrader program targets EP300-mutated cancer cells and has shown encouraging activity in ER+ breast cancer, with potential applications beyond EP300-mutant tumors [2][6][11] - The Selective EP300 degrader is being developed for hematological malignancies and prostate cancer, with updates expected in Q4 2025 [7][11] - The Selective ARID1B degrader targets ARID1B in ARID1A-mutated cancers, which are prevalent in various solid tumors, and has achieved selective degradation in preclinical studies [8][12] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for FHD-909, which is currently enrolling patients in a Phase 1 trial [4][5] - The collaboration aims to develop novel oncology medicines, leveraging both companies' strengths in drug development [4][5]